Clinical Outcomes Of Medications Post Anti-TNF: Researching Effectiveness In Pediatric IBD

Overview

About this study

The purpose of this study is to compare the effectiveness of specific therapies to treat children with CD and UC/IBD-U refractory to anti-TNF therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age < 18 years at enrollment.

  • Diagnosis of CD, UC, or IBD-U by standard diagnostic criteria.

  • Prior non-response or loss of response to one or more antiTNF agents.

  • Planning to initiate treatment with any of the following comparator agents: vedolizumab (α4β7 integrin antibody), ustekinumab (anti-IL-12/23 antibody), risankizumab, guselkumab, or mirikizumab, (IL-23 inhibitors), tofacitinib, (JAK inhibitor), and upadacitinib (JAK inhibitor). Biosimilars or generic medications for any of the above will also be allowed and handled/analyzed in an identical manner to originators.

  • Ability to provide child assent, if required per regulatory or local institutional guidelines, and parental informed consent in English or Spanish.

Exclusion Criteria:

  • Plans to change care to a different center within 1 year.

  • Prior use of a comparator agent (i.e., only patients starting their first comparator medication as monotherapy following anti-TNF will be eligible)

  • Contraindication to any of the treatments under investigation.

  • Patients with UC or IBD-U who have undergone colectomy.

  • Patients with current ostomy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/25/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Stephens

Open for enrollment

Contact information:

Mary Manyara

(507) 266-3212

Manyara.Mary@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597367

Mayo Clinic Footer